Monopar's ALXN1840 shows statistically significant copper balance improvement in Phase 2 Wilson disease trial

Monopar Therapeutics announced publication of Phase 2 study results demonstrating ALXN1840 (tiomolibdate choline) achieved statistically significant reductions in daily copper balance and increased fecal copper excretion in Wilson disease patients, with good tolerability. The positive clinical data supports advancement of the candidate for this rare genetic disorder with limited treatment options.